CURI stock has shown strong bullish momentum recently, closing at $2.59 on January 31, 2025, with an 18.81% gain during regular trading and a further 5.02% increase post-market, reaching $2.67. Analysts are optimistic, with Needham raising the price target to $3, citing the company's debt-free position and expected profitability by 2026. The stock's recent surge reflects investor confidence in its high growth potential and improving financials.